Erythropoietin: Clinical Applications

Foa, P.

doi:10.1159/000204826

Cited by 15 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to the post partum period in pregnancy, there seems to be a lack not only of iron but also of endogenous EPO under certain circumstances. These patients seem to profit from a treatment with rhEPO similar to patients with a chronic infection and low EPO levels [5,6,14]. Due to the different physiological changes, e. g., of the renal function, volume regulation and various hormonal influences, the mechanisms of erythropoiesis during pregnancy are not yet well understood.…”

Section: Discussionmentioning

confidence: 99%

“…Table I. Use of rhEPO for the treatment of pregnancy anemia related to renal disease (1)(2)(3)(4)(5) and in this study (6). In this pilot study we administered rhEPO in combination with parenteral iron to evaluate their effect in the treatment of iron deficiency anemia, supposing that there is a positive and synergistic effect of both substances in stimulating erythropoiesis.…”

Section: Curriculum Vitaementioning

confidence: 97%

See 1 more Smart Citation

Recombinant human erythropoietin and parenteral iron in the treatment of pregnancy anemia: a pilot study

Breymann

Richter²,

Huch³

et al. 1995

Jpme

View full text Add to dashboard Cite

Our aim was to correct severe iron deficiency anemia during pregnancy by using a combination therapy of recombinant human erythropoietin and parenteral iron. Eleven anemic pregnant women were treated once weekly until a hemoglobin value of 11.0 g/dl was reached. Red blood cell production was monitored by reticulocyte flow cytometry and hemoglobin increase. Iron status was assessed by serum ferritin values and transferrin saturation values. 8/11 patients showed an immediate response, noted by a continuous increase of reticulocytes, high fluorescent reticulocyte ratio and hemoglobin levels. Three patients who had lower serum ferritin values, low transferrin saturation and a lower reticulocyte count before treatment showed little response. The combination of rhEPO and parenteral iron is effective in stimulating erythropoiesis and in treating certain pregnancy anemias. This therapy could be an alternative for patients refusing blood transfusions or who are resistant to iron alone. Poor response to the treatment can be due to insufficient iron supplementation during therapy with rhEPO or due to factors that inhibit erythropoiesis during pregnancy, such as undetected infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Curriculum Vitaementioning

confidence: 97%

Recombinant human erythropoietin and parenteral iron in the treatment of pregnancy anemia: a pilot study

Breymann

Richter²,

Huch³

et al. 1995

Jpme

View full text Add to dashboard Cite

show abstract

“…Recombinant human EPO has found clinical applications in the treatment of anemias particularly those resulting from renal disease including kidney damage, anemia resulting from malignancy, AIDS or AIDS treatment, and anemia associated with myelodysplastic syndromes. [308][309][310][311] While EPO is presently the most important biotechnology product and its use has evolved into a > $7 billion/year market, its administration requires intravenous or subcutaneous injection. This situation has led to an interest in developing small-molecule mimics of EPO to replace the recombinant human protein.…”

Section: Epo/epor: Agonists From Antagonistsmentioning

confidence: 99%

Solution‐Phase Combinatorial Libraries: Modulating Cellular Signaling by Targeting Protein–Protein or Protein–DNA Interactions

2003

View full text Add to dashboard Cite

The high-throughput synthesis and screening of compound libraries hold tremendous promise for drug discovery and powerful methods for both solid-phase and solution-phase library preparation have been introduced. The question of which approach (solution-phase versus solid-phase) is best for the preparation of chemical libraries has been replaced by which approach is most appropriate for a particular target or screen. Herein we highlight distinctions in the two approaches that might serve as useful considerations at the onset of new programs. This is followed by a more personal account of our own focus on solution-phase techniques for the preparation of libraries designed to modulate cellular signaling by targeting protein-protein or protein-DNA interactions. The screening of our libraries against a prototypical set of extracellular and intracellular targets, using a wide range of assay formats, provided the first small-molecule modulators of the protein-protein interactions studied, and a generalized approach for conducting such studies.

show abstract

“…The value of r-Hu-Epo in anaemia associated with haematological disease has been reviewed by Foa [40] and Pedrazzi [41] in this journal. It is interesting to note that rHu-Epo, by increasing erythropoiesis in responders, in fact may act as an iron chelator because it mobilises iron from iron stores.…”

Section: Recombinant Human Erythropoietin An Alternative?mentioning

confidence: 99%

Iron Chelators May Enhance Erythropoiesis by Increasing Iron Delivery to Haematopoietic Tissue and Erythropoietin Response in Iron-Loading Anaemia

et al. 1993

View full text Add to dashboard Cite

Based on the mode of action of iron chelators, one might expect a decrease in bone marrow iron availability, resulting in worsening of the anaemia in certain types of iron-loading anaemia. However, improvement of anaemia or reduction in transfusion requirements during chelation treatment has been reported in various types of iron-loading anaemia. It is suggested that iron chelators act as mediators facilitating iron release from storage sites and its delivery to haematopoietic tissues. In addition, a reduction of iron stores may upregulate erythropoietin response and bring about a decrease of disease activity in inflammatory disorders, resulting in a haemoglobin rise. Large trials with (oral) iron chelators are required to verify these possible effects.

show abstract

Erythropoietin: Clinical Applications

Cited by 15 publications

References 42 publications

Recombinant human erythropoietin and parenteral iron in the treatment of pregnancy anemia: a pilot study

Recombinant human erythropoietin and parenteral iron in the treatment of pregnancy anemia: a pilot study

Solution‐Phase Combinatorial Libraries: Modulating Cellular Signaling by Targeting Protein–Protein or Protein–DNA Interactions

Iron Chelators May Enhance Erythropoiesis by Increasing Iron Delivery to Haematopoietic Tissue and Erythropoietin Response in Iron-Loading Anaemia

Contact Info

Product

Resources

About